Anti-tumour necrosis factor α therapy in rheumatoid arthritis: an update on safety
Open Access
- 1 December 2004
- journal article
- review article
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 63 (12) , 1538-1543
- https://doi.org/10.1136/ard.2004.024737
Abstract
Anti-TNFα therapy may have associated risks of serious infection, congestive heart failure, malignancy, and multiple sclerosis. The magnitude of these risks is difficult to assess. This article reviews publications on the current knowledge about the safety of these agents.Keywords
This publication has 109 references indexed in Scilit:
- PanniculitisJCR: Journal of Clinical Rheumatology, 2003
- Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor-α, in Patients With Moderate-to-Severe Heart FailureCirculation, 2003
- Post-mortem collection of human joint tissues for researchRheumatology, 2003
- Haemophagocytic syndrome in a rheumatoid arthritis patient treated with infliximabRheumatology, 2003
- Tuberculous tonsillitis in a patient receiving etanercept treatmentAnnals of the Rheumatic Diseases, 2003
- Anti-TNF-?-induced systemic lupus syndromeClinical Rheumatology, 2003
- Tumor necrosis factor antagonist therapy and lymphoma development: Twenty‐six cases reported to the Food and Drug AdministrationArthritis & Rheumatism, 2002
- How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACHInternational Journal of Cardiology, 2002
- Hepatitis with interface inflammation and IgG, IgM, and IgA anti-double-stranded DNA antibodies following infliximab therapy: Comment on the article by Charles et alArthritis & Rheumatism, 2001
- Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A proteinThe Lancet, 2001